Neuronetics, Inc. has recently received the FDA’s green light for its NeuroStar Advanced Therapy to assist in combating major depressive disorder (MDD) in adolescents aged between 15 and 21 years.
This breakthrough makes NeuroStar the inaugural FDA-endorsed transcranial magnetic stimulation (TMS) treatment tailored for this specific age bracket. TMS employs magnetic fields to invigorate nerve cells in the brain, offering relief from major depression symptoms.
An Upward Trajectory
Reflecting on the past half-year, STIM’s shares have surged by an impressive 263.4%, significantly outperforming the medical instruments industry’s 22.4% upturn and the S&P 500’s modest 22.1% rise.
Image Source: Zacks Investment Research
Analyzing the Impact
The period following the COVID-19 outbreak has witnessed a surge in depression cases among teenagers and young adults. The treatment options for this age group have traditionally been limited when compared to therapies for adults.
With its TMS therapy, NeuroStar introduces a promising primary treatment avenue for adolescents, boasting response rates comparable to those seen in adults. This milestone could herald a paradigm shift in addressing depression among young individuals.
The FDA’s approval hinged partly on the real-world data insights produced by NeuroStar’s TrakStar technology. Out of 1,169 teenagers analyzed for depression severity, a staggering 78% witnessed significant clinical improvement, underpinning the treatment’s efficacy.
The FDA’s analysis, which encompassed a broad dataset from TrakStar and published clinical literature, underscored the profound safety and efficacy of NeuroStar TMS when used as an adjunct to antidepressant therapy in this demographic.
By leveraging its coil architecture’s adaptability, NeuroStar empowers healthcare providers to swiftly address the MDD symptoms of teenagers, eliminating the need for additional equipment expenses or modifications.
Unveiling Market Potential
According to a Mordor Intelligence report, the global market for anxiety disorders and depression treatment is projected to reach $27.9 billion by 2029, climbing from $21.5 billion in 2024 at a growth rate of 5.3%.
The anticipated upswing is fueled by factors like increasing depression and anxiety disorder incidences, heightened awareness, and new product releases from leading industry players.
In the context of the expanding depression treatment market, NeuroStar Advanced Therapy’s FDA clearance is poised to bolster Neuronetics’ market presence, potentially lifting revenues.
Recent Strides
In a recent development, Neuronetics cemented an expanded commercial alliance with Transformations Care Network, a mental healthcare provider. This collaboration marks a significant progression in mental health treatment, particularly for patients grappling with MDD and treatment-resistant depression.
Neuronetics, Inc. Price
Neuronetics, Inc. price | Neuronetics, Inc. Quote
Assessment of Zacks Rank & Promising Stocks
Currently holding a Zacks Rank #3 (Hold), STIM remains a stock to monitor.
In the broader medical sector, some noteworthy stocks include DaVita Inc. DVA, Cardinal Health, Inc. CAH, and Cencora, Inc. COR.
DaVita, crowned with a Zacks Rank #1 (Strong Buy), boasts an estimated long-term growth rate of 12.1%. Over the past four quarters, DVA has consistently surpassed earnings estimates, with an average surprise of 35.6%. To explore today’s top Zacks #1 Rank stocks, check out the full list here.
DaVita’s shares have surged by 58.3% in the past year, outperforming the industry’s 18.9% increase.
Meanwhile, Cardinal Health, holding a Zacks Rank #1, anticipates a long-term growth rate of 14.2%. CAH has continuously outpaced earnings projections over the last four quarters, with an average beat of 15.6%.
Cardinal Health’s shares have jumped by 51.9% in the past year, eclipsing the industry’s 3.2% rise.
On the other hand, Cencora stands at a Zacks Rank #2 (Buy), with a projected long-term growth rate of 9.8%. COR has consistently surpassed earnings estimates over the course of the last four quarters, with an average beat of 6.7%.
Cencora’s shares have soared by 51.5% in the past year, surpassing the industry’s 3.6% upswing.
Unlock Zacks’ Expert Insights for Just $1
No gimmicks.
A few years back, Zacks took the finance world by storm, offering a 30-day peek at all their recommendations for a mere $1. No strings attached.
Thousands seized this opportunity, while some hesitated, suspecting a catch. Yes, there is a purpose. Zacks wanted prospective investors to explore their array of services like Surprise Trader, Stocks Under $10, Technology Innovators, and more. In 2023 alone, these services closed 162 positions with massive gains in the double and triple digits.
The opinions and beliefs expressed here are solely those of the author and not necessarily those of Nasdaq, Inc.
